Cargando…

Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5

Truncated-ERBB2 isoforms (t-ERBB2s), resulting from receptor proteolysis or alternative translation of the ERBB2 mRNA, exist in a subset of human breast tumors. t-ERBB2s lack the receptor extracellular domain targeted by therapeutic anti-ERBB2 antibodies and antibody–drug conjugates, including trast...

Descripción completa

Detalles Bibliográficos
Autores principales: Ward, T M, Iorns, E, Liu, X, Hoe, N, Kim, P, Singh, S, Dean, S, Jegg, A-M, Gallas, M, Rodriguez, C, Lippman, M, Landgraf, R, Pegram, M D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655379/
https://www.ncbi.nlm.nih.gov/pubmed/22751112
http://dx.doi.org/10.1038/onc.2012.256
_version_ 1782269873884233728
author Ward, T M
Iorns, E
Liu, X
Hoe, N
Kim, P
Singh, S
Dean, S
Jegg, A-M
Gallas, M
Rodriguez, C
Lippman, M
Landgraf, R
Pegram, M D
author_facet Ward, T M
Iorns, E
Liu, X
Hoe, N
Kim, P
Singh, S
Dean, S
Jegg, A-M
Gallas, M
Rodriguez, C
Lippman, M
Landgraf, R
Pegram, M D
author_sort Ward, T M
collection PubMed
description Truncated-ERBB2 isoforms (t-ERBB2s), resulting from receptor proteolysis or alternative translation of the ERBB2 mRNA, exist in a subset of human breast tumors. t-ERBB2s lack the receptor extracellular domain targeted by therapeutic anti-ERBB2 antibodies and antibody–drug conjugates, including trastuzumab, trastuzumab-DM1 and pertuzumab. In clinical studies, expression of t-ERBB2 in breast tumors correlates with metastasis as well as trastuzumab resistance. By using a novel immuno-microarray method, we detect a significant t-ERBB2 fraction in 18 of 31 (58%) of immunohistochemistry (IHC)3+ ERBB2+ human tumor specimens, and further show that t-ERBB2 isoforms are phosphorylated in a subset of IHC3+ samples (10 of 31, 32%). We investigated t-ERBB2 biological activity via engineered expression of full-length and truncated ERBB2 isoforms in human mammary epithelial cells (HMECs), including HMEC and MCF10A cells. Expression of p110 t-ERBB2, but not p95m (m=membrane, also 648CTF) or intracellular ERBB2s, significantly enhanced cell migration and invasion in multiple cell types. In addition, only expression of the p110 isoform led to human breast epithelial cell (HMLE) xenograft formation in vivo. Expression of t-ERBB2s did not result in hyperactivation of the phosphoinositide kinase-3/AKT or mitogen-activated protein kinase signaling pathways in these cells; rather, phosphoproteomic array profiling revealed attenuation of phosphorylated signal transducer and activator of transcription 5 (STAT5) in p110-t-ERBB2-expressing cells compared to controls. Short hairpin-mediated silencing of STAT5 phenocopied p110-t-ERBB2-driven cell migration and invasion, while expression of constitutively active STAT5 reversed these effects. Thus, we provide novel evidence that (1) expression of p110 t-ERBB2 is sufficient for full transformation of HMEC, yielding in vivo xenograft formation, and (2) truncated p110 t-ERBB2 expression is associated with decreased phosphorylation of STAT5.
format Online
Article
Text
id pubmed-3655379
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36553792013-05-17 Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5 Ward, T M Iorns, E Liu, X Hoe, N Kim, P Singh, S Dean, S Jegg, A-M Gallas, M Rodriguez, C Lippman, M Landgraf, R Pegram, M D Oncogene Original Article Truncated-ERBB2 isoforms (t-ERBB2s), resulting from receptor proteolysis or alternative translation of the ERBB2 mRNA, exist in a subset of human breast tumors. t-ERBB2s lack the receptor extracellular domain targeted by therapeutic anti-ERBB2 antibodies and antibody–drug conjugates, including trastuzumab, trastuzumab-DM1 and pertuzumab. In clinical studies, expression of t-ERBB2 in breast tumors correlates with metastasis as well as trastuzumab resistance. By using a novel immuno-microarray method, we detect a significant t-ERBB2 fraction in 18 of 31 (58%) of immunohistochemistry (IHC)3+ ERBB2+ human tumor specimens, and further show that t-ERBB2 isoforms are phosphorylated in a subset of IHC3+ samples (10 of 31, 32%). We investigated t-ERBB2 biological activity via engineered expression of full-length and truncated ERBB2 isoforms in human mammary epithelial cells (HMECs), including HMEC and MCF10A cells. Expression of p110 t-ERBB2, but not p95m (m=membrane, also 648CTF) or intracellular ERBB2s, significantly enhanced cell migration and invasion in multiple cell types. In addition, only expression of the p110 isoform led to human breast epithelial cell (HMLE) xenograft formation in vivo. Expression of t-ERBB2s did not result in hyperactivation of the phosphoinositide kinase-3/AKT or mitogen-activated protein kinase signaling pathways in these cells; rather, phosphoproteomic array profiling revealed attenuation of phosphorylated signal transducer and activator of transcription 5 (STAT5) in p110-t-ERBB2-expressing cells compared to controls. Short hairpin-mediated silencing of STAT5 phenocopied p110-t-ERBB2-driven cell migration and invasion, while expression of constitutively active STAT5 reversed these effects. Thus, we provide novel evidence that (1) expression of p110 t-ERBB2 is sufficient for full transformation of HMEC, yielding in vivo xenograft formation, and (2) truncated p110 t-ERBB2 expression is associated with decreased phosphorylation of STAT5. Nature Publishing Group 2013-05-09 2012-07-02 /pmc/articles/PMC3655379/ /pubmed/22751112 http://dx.doi.org/10.1038/onc.2012.256 Text en Copyright © 2013 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Original Article
Ward, T M
Iorns, E
Liu, X
Hoe, N
Kim, P
Singh, S
Dean, S
Jegg, A-M
Gallas, M
Rodriguez, C
Lippman, M
Landgraf, R
Pegram, M D
Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5
title Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5
title_full Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5
title_fullStr Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5
title_full_unstemmed Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5
title_short Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5
title_sort truncated p110 erbb2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated stat5
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655379/
https://www.ncbi.nlm.nih.gov/pubmed/22751112
http://dx.doi.org/10.1038/onc.2012.256
work_keys_str_mv AT wardtm truncatedp110erbb2inducesmammaryepithelialcellmigrationinvasionandorthotopicxenograftformationandisassociatedwithlossofphosphorylatedstat5
AT iornse truncatedp110erbb2inducesmammaryepithelialcellmigrationinvasionandorthotopicxenograftformationandisassociatedwithlossofphosphorylatedstat5
AT liux truncatedp110erbb2inducesmammaryepithelialcellmigrationinvasionandorthotopicxenograftformationandisassociatedwithlossofphosphorylatedstat5
AT hoen truncatedp110erbb2inducesmammaryepithelialcellmigrationinvasionandorthotopicxenograftformationandisassociatedwithlossofphosphorylatedstat5
AT kimp truncatedp110erbb2inducesmammaryepithelialcellmigrationinvasionandorthotopicxenograftformationandisassociatedwithlossofphosphorylatedstat5
AT singhs truncatedp110erbb2inducesmammaryepithelialcellmigrationinvasionandorthotopicxenograftformationandisassociatedwithlossofphosphorylatedstat5
AT deans truncatedp110erbb2inducesmammaryepithelialcellmigrationinvasionandorthotopicxenograftformationandisassociatedwithlossofphosphorylatedstat5
AT jeggam truncatedp110erbb2inducesmammaryepithelialcellmigrationinvasionandorthotopicxenograftformationandisassociatedwithlossofphosphorylatedstat5
AT gallasm truncatedp110erbb2inducesmammaryepithelialcellmigrationinvasionandorthotopicxenograftformationandisassociatedwithlossofphosphorylatedstat5
AT rodriguezc truncatedp110erbb2inducesmammaryepithelialcellmigrationinvasionandorthotopicxenograftformationandisassociatedwithlossofphosphorylatedstat5
AT lippmanm truncatedp110erbb2inducesmammaryepithelialcellmigrationinvasionandorthotopicxenograftformationandisassociatedwithlossofphosphorylatedstat5
AT landgrafr truncatedp110erbb2inducesmammaryepithelialcellmigrationinvasionandorthotopicxenograftformationandisassociatedwithlossofphosphorylatedstat5
AT pegrammd truncatedp110erbb2inducesmammaryepithelialcellmigrationinvasionandorthotopicxenograftformationandisassociatedwithlossofphosphorylatedstat5